Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients

  |  Issue: August 2020  |  

This review showed that IL-17 inhibitors produce a favorable response rate, but at an increased risk of non-severe infections in patients with active AS.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Yin Y, Wang M, Liu M, et al. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Arthritis Res Ther. 2020 May 12;22(1):111.

Related Articles
    A New Treatment for Axial Spondyloarthritis?

    A New Treatment for Axial Spondyloarthritis?

    If approved by the U.S. Food and Drug Administration (FDA), difficult-to-treat patients with axial spondyloarthritis who fail or are intolerant to standard treatment with tumor necrosis factor inhibitors (TNFi) may have a new treatment option. That new option is a high-affinity monoclonal antibody, called ixekizumab, which selectively targets an area linked to the immunopathology of…

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…